Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 3
2008 1
2012 2
2013 2
2014 2
2016 4
2017 1
2018 1
2019 1
2020 3
Text availability
Article attribute
Article type
Publication date

Search Results

17 results
Results by year
Filters applied: . Clear all
Page 1
A case of ischemic gastroduodenal disease in a patient who was receiving hemodialysis treatment that was managed by conservative treatment.
Tomishima K, Sato S, Amano N, Murata A, Tsuzura H, Sato S, Kanemitsu Y, Shimada Y, Iijima K, Genda T, Wada R, Nagahara A. Tomishima K, et al. Among authors: iijima k. Clin J Gastroenterol. 2018 Oct;11(5):386-390. doi: 10.1007/s12328-018-0865-1. Epub 2018 May 8. Clin J Gastroenterol. 2018. PMID: 29737481 Review.
A case of primary biliary cholangitis overlapping with type 2 autoimmune hepatitis.
Amano N, Sato S, Murata A, Tsuzura H, Tomishima K, Sato S, Matsumoto K, Shimada Y, Iijima K, Harada K, Genda T. Amano N, et al. Among authors: iijima k. Clin J Gastroenterol. 2020 Feb;13(1):79-82. doi: 10.1007/s12328-019-01017-2. Epub 2019 Jul 8. Clin J Gastroenterol. 2020. PMID: 31286423
[GERD and tight junction proteins of the esophageal mucosa].
Miwa H, Asaoka D, Hojo M, Iijima K, Sato N. Miwa H, et al. Among authors: iijima k. Nihon Rinsho. 2004 Aug;62(8):1441-6. Nihon Rinsho. 2004. PMID: 15344532 Review. Japanese.
Pretreatment AKR1B10 expression predicts the risk of hepatocellular carcinoma development after hepatitis C virus eradication.
Murata A, Genda T, Ichida T, Amano N, Sato S, Tsuzura H, Sato S, Narita Y, Kanemitsu Y, Shimada Y, Hirano K, Iijima K, Wada R, Nagahara A, Watanabe S. Murata A, et al. Among authors: iijima k. World J Gastroenterol. 2016 Sep 7;22(33):7569-78. doi: 10.3748/wjg.v22.i33.7569. World J Gastroenterol. 2016. PMID: 27672277 Free PMC article.
Aldo-keto reductase family 1 member B10 is associated with hepatitis B virus-related hepatocellular carcinoma risk.
Mori M, Genda T, Ichida T, Murata A, Kamei M, Tsuzura H, Sato S, Narita Y, Kanemitsu Y, Ishikawa S, Kikuchi T, Shimada Y, Hirano K, Iijima K, Sugimoto K, Wada R, Nagahara A, Watanabe S. Mori M, et al. Among authors: iijima k. Hepatol Res. 2017 Mar;47(3):E85-E93. doi: 10.1111/hepr.12725. Epub 2016 May 11. Hepatol Res. 2017. PMID: 27084455
Impact of aldo-keto reductase family 1 member B10 on the risk of hepatitis C virus-related hepatocellular carcinoma.
Sato S, Genda T, Ichida T, Murata A, Tsuzura H, Narita Y, Kanemitsu Y, Ishikawa S, Kikuchi T, Mori M, Hirano K, Iijima K, Wada R, Nagahara A, Watanabe S. Sato S, et al. Among authors: iijima k. J Gastroenterol Hepatol. 2016 Jul;31(7):1315-22. doi: 10.1111/jgh.13295. J Gastroenterol Hepatol. 2016. PMID: 26758591
Prediction of Hepatocellular Carcinoma Development after Hepatitis C Virus Eradication Using Serum Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein.
Sato S, Genda T, Ichida T, Amano N, Sato S, Murata A, Tsuzura H, Narita Y, Kanemitsu Y, Hirano K, Shimada Y, Iijima K, Wada R, Nagahara A, Watanabe S. Sato S, et al. Among authors: iijima k. Int J Mol Sci. 2016 Dec 20;17(12):2143. doi: 10.3390/ijms17122143. Int J Mol Sci. 2016. PMID: 27999409 Free PMC article.
Prediction of liver stiffness hepatocellular carcinoma in chronic hepatitis C patients on interferon-based anti-viral therapy.
Narita Y, Genda T, Tsuzura H, Sato S, Kanemitsu Y, Ishikawa S, Kikuchi T, Hirano K, Iijima K, Wada R, Ichida T. Narita Y, et al. Among authors: iijima k. J Gastroenterol Hepatol. 2014 Jan;29(1):137-43. doi: 10.1111/jgh.12401. J Gastroenterol Hepatol. 2014. PMID: 24117602
Prognostic significance of serum tyrosine concentration in patients with primary biliary cholangitis under ursodeoxycholic acid therapy.
Amano N, Ikeda Y, Hayashida S, Takahashi S, Sato S, Murata A, Tsuzura H, Sato S, Shimada Y, Iijima K, Wada R, Nagahara A, Genda T. Amano N, et al. Among authors: iijima k. Hepatol Res. 2020 Feb;50(2):214-223. doi: 10.1111/hepr.13434. Epub 2020 Jan 5. Hepatol Res. 2020. PMID: 31652380
On-treatment Serum Mac-2 Binding Protein Glycosylation Isomer (M2BPGi) Level and Risk of Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B during Nucleot(s)ide Analogue Therapy.
Murata A, Amano N, Sato S, Tsuzura H, Tomishima K, Sato S, Matsumoto K, Shimada Y, Iijima K, Genda T. Murata A, et al. Among authors: iijima k. Int J Mol Sci. 2020 Mar 17;21(6):2051. doi: 10.3390/ijms21062051. Int J Mol Sci. 2020. PMID: 32192084 Free PMC article.
17 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback